Tagged: exosomes
3 results
PranaX
PranaX is a Houston-based regenerative medicine biotechnology company developing stem cell-derived exosome products to counter aging, inflammation, and tissue damage. Built on exosome technology exclusively licensed from The University of Texas MD Anderson Cancer Center, PranaX operates an FDA-registered cGMP facility at the Levit Green life science campus and is bringing to market a physician-directed exosome wellness supplement (ExoWELL) and a personal exosome banking service (ExoSTORE). The company closed an oversubscribed $17M Series A in early 2026.
Phillip Maderia
Phillip Maderia is the Chief Executive Officer of PranaX, a Houston-based regenerative-medicine biotech developing stem cell-derived exosome products at the Levit Green campus in the Texas Medical Center. He joined in March 2025 after four years running Lonza's exosome manufacturing site in Lexington, Massachusetts - the facility Lonza bought from Codiak BioSciences in 2021, where Maderia had previously served as VP of Manufacturing Operations. He is a career biomanufacturing operator with roots at Sanofi Genzyme and LFB-USA and roughly three decades of scale-up experience.
Tom Benson
Tom Benson is the founder and CEO of Mitrix Bio, a Pleasanton, California biotech building toward whole-body mitochondrial transplantation. A serial software, hardware, and science entrepreneur, he managed the Linac Coherent Light Source femtosecond X-ray laser at Stanford's SLAC before turning his attention to the cell's power plants. His pitch is audacious and specific: grow young mitochondria from a person's own stem cells in a bioreactor, then transfuse them back to restore cellular energy and push the human lifespan toward 130 years.